Oncology Practice Management - June 2014, Vol 4, No 4

View Digital Edition
The following interview was conducted recently with Vicki Kennedy, LCSW, at the 2014 conference of the Association for Value-Based Cancer Care. Read More ›

Regardless of which version you are considering, the International Classification of Diseases, Clinical Modification (ICD-CM) is a morbidity classification published by the United States for classifying diagnoses and reasons for visits in all healthcare settings. Read More ›

My grandmother always told me, “Buy the best you can afford.” Contained in this simple advice, something we all have likely heard in one form or another, are a couple of key concepts worth extracting as they pertain to the oncology industry: the words “buy” and “best.” Read More ›

Managing the compounding and handling of hazardous drugs has always been complicated, but it is the cornerstone of the care we provide. These drugs offer hope to patients battling cancer. Read More ›

Recent media co­v­­er­age of the de­-bate surrounding an increased federal minimum wage as well as increased “salary basis” test to determine exempt status has drawn employers’ attention. Read More ›

Part 1 of this 3-part series focuses on pretransactional due diligence and structural design processes as they pertain to physician–hospital alignments. Part 2 of this series will address governance and compensation plans; the final installment will discuss ongoing relationships and planning for a potential “divorce.” Read More ›

The following sections will assist healthcare professionals and payers by providing appropriate coding and billing information associated with the treatment of lung cancer. Read More ›

The following clinical trials are currently recruiting patients with renal cell carcinoma (RCC) for inclusion in several investigations. Each trial description includes the NLM Identifier to use as reference with ClinicalTrials.gov. Read More ›

Chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults, is a cancer of B-cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing an immune response. Read More ›

This article is the first in a series of 5 articles to run in Oncology Practice Management on patient assistance programs. The information below—highlighting an assistance program for patients who are prescribed Im­­bruvica—was provided by Phar­macyclics, Inc, and Janssen Biotech, Inc. Read More ›

Subscribe to
Rheumatology Practice Management

Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or weekly e‑Newsletter.

I'd like to receive: